apelin
famili
peptid
activ
apelin
receptor
also
known
apj
emerg
import
physiolog
pathophysiolog
cardiovascular
system
yang
et
al
apelin
peptid
present
human
vascular
cardiac
endotheli
cell
kleinz
davenport
plasma
identifi
abund
cardiovascular
isoform
de
mota
et
al
maguir
et
al
zhen
et
al
apelin
mediat
three
major
action
vitro
interact
apelin
receptor
cardiac
myocyt
caus
increas
cardiac
contractil
inotrop
action
apelin
order
magnitud
potent
vessel
intact
endothelium
apelin
act
releas
vasodil
may
oppos
action
vasoconstrictor
also
shown
remov
endothelium
unmask
constrictor
respons
mediat
apelin
receptor
present
vascular
smooth
muscl
maguir
et
al
importantli
healthi
volunt
heart
failur
patient
major
effect
apelin
infus
forearm
vivo
nitric
oxid
depend
arteri
dilat
japp
et
al
barn
et
al
brame
et
al
heart
failur
patient
intracoronari
caus
coronari
vasodilat
increas
cardiac
contractil
japp
et
al
barn
et
al
system
infus
volunt
patient
increas
cardiac
index
lower
mean
arteri
blood
pressur
peripher
vascular
resist
japp
et
al
barn
et
al
apelin
downregul
pulmonari
arteri
hypertens
pah
devast
diseas
character
vascular
remodel
result
progress
obliter
pulmonari
circul
lead
right
ventricl
rv
hypertrophi
right
heart
failur
alastalo
et
al
chandra
et
al
therefor
apelin
receptor
may
repres
novel
target
futur
drug
develop
human
angiotensin
convert
enzym
sequenc
similar
ctermin
dipeptidylpeptidas
ace
donoghu
et
al
tipni
et
al
express
exampl
heart
kidney
lung
donoghu
et
al
ham
et
al
implic
patholog
condit
heart
failur
upregul
zisman
et
al
goulter
et
al
major
role
degrad
angiotensin
ii
angiotensin
act
benefici
vasodil
antiprolifer
agent
counterbalanc
action
vasoconstrictor
angiotensin
ii
santo
et
al
also
viral
receptor
sever
acut
respiratori
syndrom
coronaviru
li
et
al
downregul
enzym
cell
surfac
result
angiotensin
iiinduc
lung
injuri
kuba
et
al
ration
develop
recombin
human
clinic
trial
acut
lung
injuri
haschk
et
al
interestingli
enhanc
activ
pharmacolog
gene
transfer
effect
prevent
revers
pah
shenoy
et
al
dai
et
al
benefici
action
thought
mediat
convers
angiotensin
ii
angiotensin
howev
possibl
interact
peptid
clear
screen
biolog
activ
peptid
report
two
other
hydrolyz
high
catalyt
effici
dynorphin
report
vasoact
result
remov
ctermin
phenylalanin
produc
metabolit
vicker
et
al
loss
termin
phenylalanin
apelin
assum
mechan
degrad
inactiv
peptid
aim
understand
impact
cleavag
reaction
apelin
signal
pathway
specif
object
firstli
confirm
figur
produc
hydrolysi
find
evid
endogen
peptid
determin
distribut
human
cardiovascular
tissu
secondli
demonstr
bind
apelin
receptor
activ
downstream
signal
pathway
cell
base
assay
thirdli
determin
retain
signific
biolog
activ
compar
previous
report
data
maguir
et
al
brame
et
al
vitro
use
vascular
cardiac
human
rodent
tissu
system
infus
vivo
rat
final
sinc
predomin
action
apelin
infus
human
forearm
vasodilat
perform
firstinman
studi
explor
physiolog
action
peptid
healthi
volunt
also
wish
explor
structur
activ
relationship
sar
apelin
peptid
therefor
addit
experi
perform
ntermin
extend
put
endogen
peptid
alanin
substitut
shorter
fragment
figur
data
expand
knowledg
structur
activ
relationship
apelin
peptid
demonstr
signific
biolog
activ
metabolit
data
support
hypothesi
therapeut
strategi
enhanc
activ
upregul
cardiovascular
diseas
may
result
enhanc
breakdown
may
significantli
compromis
benefici
effect
endogen
apelin
signal
via
gener
human
tissu
sampl
obtain
inform
consent
papworth
hospit
research
tissu
bank
local
ethic
approv
synthesi
confirm
incub
nmol
enzym
pmol
gsk
ware
uk
buffer
ph
contain
nmorpholino
ethanesulfon
acid
me
mmoll
nacl
mmoll
h
follow
quench
ethylenediaminetetraacet
acid
edta
see
vicker
et
al
similar
protocol
reaction
mixtur
analyz
malditof
mass
spectrometri
sampl
desalt
use
millipor
usa
wash
acet
acid
elut
chca
matrix
aqueou
acetonitril
contain
trifluoroacet
acid
stainless
steel
sampl
slide
sampl
air
dri
analyz
use
water
maldi
micromx
timeofflight
mass
spectromet
usa
calibr
extern
use
polyethylen
glycol
hzlaser
power
threshold
spectra
sum
shot
collect
spiral
track
sampl
area
data
process
use
water
masslynx
softwar
usa
control
reaction
includ
incub
nmol
incub
nmol
nmol
without
incub
pmol
without
peptid
peroxidaseantiperoxidas
duallabel
immunofluoresc
stain
conduct
describ
kleinz
et
al
use
frozen
section
human
cardiomyopathi
heart
n
histolog
normal
n
pah
n
lung
affin
purifi
rabbitanti
antiserum
dilut
custom
synthes
antibodi
rais
relev
apelin
peptid
fragment
ckgpmp
lack
ctermin
phenylalanin
select
confirm
comparison
correspond
fragment
contain
ctermin
phenylalanin
ckgpmpf
elisa
figur
contrast
commerci
avail
antibodi
phoenix
pharmaceut
inc
ca
usa
cross
react
figur
r
system
mn
usa
abcam
cambridg
uk
antisera
also
use
von
willebrand
factor
vwf
dako
glostrup
denmark
use
endotheli
marker
peroxidas
stain
section
examin
bright
field
microscop
olympu
southendonsea
uk
imag
use
camera
celld
soft
imag
system
olympu
wherea
fluoresc
stain
imag
use
leica
scan
confoc
microscop
tc
leica
microsystem
milton
keyn
uk
imag
process
roll
ball
method
histogram
redistribut
appli
equal
entir
imag
channel
overlay
carri
use
imagej
assay
perform
human
heart
previous
describ
brame
et
al
briefli
homogen
human
left
ventricl
lv
incub
min
nmoll
assay
buffer
mmoll
tri
ph
presenc
increas
concentr
sar
singl
concentr
nonspecif
bind
defin
use
equilibrium
broken
centrifug
g
min
pellet
wash
trishcl
buffer
mmoll
ph
recentrifug
pellet
count
detect
bound
radioact
competit
bind
data
analyz
use
graphpad
prism
graphpad
softwar
inc
la
jolla
ca
usa
obtain
valu
pki
neg
dissoci
constant
deriv
compet
ligand
radioligand
concentr
radioligand
affin
cheng
prusoff
equat
experi
perform
triplic
inhibit
camp
accumul
recruit
receptor
intern
apelin
isoform
modifi
truncat
apelin
peptid
studi
use
cell
express
human
apelin
receptor
discoverx
ca
usa
per
manufactur
instruct
assay
result
chemiluminesc
signal
measur
rel
light
unit
rlu
use
micropl
reader
discoverx
fremont
ca
camp
assay
forskolin
use
stimul
camp
product
concentrationrespons
curv
construct
nmoll
agonist
respons
express
forskolin
respons
intern
assay
concentrationrespons
curv
construct
nmoll
agonist
respons
express
maximum
respons
data
analyz
use
logist
equat
use
graphpad
prism
determin
valu
potenc
concentr
produc
half
maxim
respons
maximum
respons
emax
nvalu
given
number
replicatesnumb
experi
use
data
camp
assay
predomin
cardiac
isoform
use
refer
ligand
rel
activ
g
proteindepend
independ
signal
pathway
compar
use
bia
analysi
describ
van
der
westhuizen
et
al
addit
assay
experi
perform
incub
describ
assay
control
concentrationrespons
curv
construct
compar
concentrationrespons
curv
construct
agonist
follow
preincub
vascular
smooth
muscl
apelin
receptormedi
contract
exploit
bioassay
compar
vitro
potenc
apelin
peptid
experi
carri
previous
describ
maguir
endotheliumdenud
saphen
vein
concentrationrespons
curv
construct
nmoll
agonist
respons
express
termin
respons
kcl
mmoll
inotrop
action
determin
mous
pace
rv
n
comparison
two
sampl
human
pace
atrial
appendag
strip
describ
maguir
et
al
data
express
termin
respons
data
vascular
cardiac
experi
analyz
use
logist
curv
graphpad
prism
determin
valu
emax
experi
perform
accord
local
ethic
committe
univers
colleg
london
home
offic
uk
guidelin
scientif
procedur
act
conform
direct
effect
system
infus
increment
bolu
dose
blood
pressur
heart
rate
stroke
volum
cardiac
output
assess
male
wistar
rat
g
bodi
weight
describ
brame
et
al
anesthet
isofluran
induct
mainten
continu
monitor
throughout
left
carotid
arteri
right
jugular
vein
cannul
mm
polyvinyl
chlorid
tube
mean
arteri
pressur
map
measur
throughout
procedur
via
pressur
transduc
powerlab
ad
instrument
chalgrov
uk
connect
arteri
line
baselin
hemodynam
record
use
chart
acquisit
softwar
channel
powerlab
system
ad
instrument
chalgrov
uk
min
stabil
period
thorac
echocardiographi
perform
scan
depth
cm
use
mhz
probe
vivid
dimens
ge
healthcar
bedford
uk
pulsedwav
doppler
use
determin
aortic
blood
flow
veloc
aortic
arch
stroke
volum
sv
determin
product
integr
vti
vessel
crosssect
area
data
six
consecut
cardiac
cycl
use
determin
heart
rate
hr
marker
left
ventricular
contractil
peak
veloc
pv
valu
sv
hr
use
calcul
cardiac
output
co
respir
rate
determin
movement
diaphragm
use
timemot
model
end
studi
rat
euthan
intraven
pentobarbiton
exsanguin
studi
perform
healthi
volunt
n
univers
cambridg
vascular
research
unit
addenbrook
hospit
cambridg
uk
volunt
characterist
given
tabl
studi
carri
accord
recommend
nation
research
ethic
servic
committe
east
englandcambridg
central
written
inform
consent
subject
subject
gave
written
inform
consent
accord
declar
helsinki
protocol
approv
nation
research
ethic
servic
committe
east
englandcambridg
central
rec
chang
forearm
blood
flow
fbf
respons
nmolmin
measur
previous
describ
brame
et
al
exclus
criteria
ischem
heart
diseas
respiratori
renal
neurolog
diseas
diabet
mellitu
hypertens
bmi
bmi
smoker
pregnant
use
vasoact
medic
nsaidsaspirin
within
h
studi
current
involv
research
studi
omron
oscillimetr
sphygmomanomet
use
measur
blood
pressur
heart
rate
baselin
everi
min
contralater
arm
period
cuff
around
upper
arm
inflat
mmhg
deflat
interrupt
venou
return
min
measur
hand
circul
exclud
inflat
wrist
cuff
mmhg
chang
forearm
volum
measur
mercuryinsilast
strain
gaug
fbf
subsequ
express
ml
forearm
volum
per
min
infus
peptid
via
cathet
portex
kent
uk
brachial
arteri
nondomin
arm
cannul
needl
cooper
needl
work
birmingham
uk
local
anesthesia
lignocain
hameln
pharmaceut
ltd
gloucest
uk
fbf
measur
arm
respons
present
absolut
chang
forearm
blood
flow
preinfus
baselin
valu
suppli
seal
glass
vial
store
requir
allow
warm
room
temperatur
dilut
physiolog
salin
produc
stock
solut
filter
flat
filter
portex
hyth
uk
dilut
salin
infus
three
increment
dose
visit
dose
previous
optim
pilot
studi
dose
infus
min
min
salin
infus
washout
period
next
dose
administ
end
studi
sodium
nitroprussid
infus
min
posit
control
follow
salin
infus
neg
control
measur
mean
standard
error
mean
sem
data
analysi
statist
test
perform
use
graphpad
prism
determin
valu
affin
pki
calcul
competit
valu
use
cheng
prusoff
equat
potenc
concentr
produc
maximum
respons
maximum
respons
emax
appropri
cell
assay
valu
compar
oneway
anova
follow
tukey
multipl
comparison
test
rat
vivo
experi
effect
bp
pv
vti
express
chang
vehicl
control
anim
variabl
sv
co
express
absolut
valu
effect
increas
dose
paramet
compar
baselin
vehicl
control
use
repeat
measur
one
way
anova
follow
dunnett
multipl
comparison
test
similarli
human
fbf
studi
respons
success
increas
dose
compar
preinfus
baselin
valu
use
repeat
measur
oneway
anova
follow
dunnett
multipl
comparison
test
chemic
reagent
purchas
sigma
pool
uk
unless
otherwis
state
custom
synthes
glp
standard
use
fmoc
chemistri
solid
phase
support
matrix
puriti
malditof
mass
spectroscopi
rphplc
analysi
peptid
test
steril
demonstr
pyrogen
free
biolog
activ
confirm
use
assay
apelin
peptid
synthes
severn
biotech
kidderminst
uk
shown
mass
spectra
figur
figur
alon
produc
signal
mz
respect
incub
result
signal
masstocharg
ratio
correspond
de
novo
gener
weak
signal
repres
remain
parent
peptid
figur
contrast
incub
figur
produc
shorter
apelin
fragment
final
enzym
alon
figur
result
interf
signal
relev
mass
rang
endogen
peptid
detect
human
cardiovascular
tissu
local
endothelium
figur
like
immunoreact
li
detect
vascular
figur
endocardi
figur
endothelium
identifi
posit
stain
vwf
figur
section
human
cardiomyopathi
heart
express
report
increas
zisman
et
al
goulter
et
al
li
figur
vwfli
figur
also
coexpress
figur
human
lung
importantli
li
figur
figur
coloc
figur
pulmonari
blood
vessel
importantli
apelin
reduc
pah
presenc
investig
section
human
pah
lung
compar
normal
lung
figur
li
detect
vascular
endothelium
pah
lung
figur
l
compet
bind
nanomolar
affin
pki
n
lower
parent
molecul
pki
n
figur
exhibit
compar
affin
pki
n
wherea
extend
peptid
compet
highest
affin
pki
n
shorter
fragment
compet
specif
bind
wherea
less
effect
compet
respect
signal
assay
inhibit
forskolinstimul
camp
product
subnanomolar
potenc
n
less
potent
refer
agonist
n
compar
n
n
time
potent
ligand
fulli
inhibit
camp
product
figur
retain
nanomolar
potenc
n
wherea
inhibit
incomplet
g
proteinindepend
recruit
assay
n
n
n
less
potent
camp
assay
potent
interestingli
unlik
shorter
peptid
exhibit
compar
potenc
agonist
camp
assay
n
figur
n
less
potent
curv
incomplet
similar
assay
intern
assay
less
potent
peptid
full
agonist
compar
efficaci
valu
emax
valu
respect
figur
compar
camp
data
three
endogen
peptid
refer
agonist
analysi
tabl
demonstr
bia
factor
indic
compar
g
protein
bias
markedli
bias
recruit
assay
significantli
potent
p
incub
p
incub
p
combin
exhibit
compar
potenc
p
tabl
therefor
reaction
product
close
resembl
emax
n
emax
n
contract
saphen
vein
compar
subnanomolar
potenc
maximum
respons
figur
data
previous
obtain
assay
brame
et
al
mous
pace
rv
produc
concentrationdepend
increas
forc
contract
emax
n
figur
compar
isoprenalin
emax
n
figur
limit
human
atrial
appendag
strip
avail
test
inotrop
action
tissu
two
patient
act
posit
inotrop
subnanomolar
potenc
valu
emax
n
anesthet
rat
n
elicit
dosedepend
decreas
bp
figur
decreas
bp
significantli
differ
p
baselin
dose
nmol
cardiac
paramet
sv
co
pv
vti
alter
figur
human
volunt
n
figur
produc
compar
dosedepend
increas
forearm
blood
flow
shown
brame
et
al
signific
effect
either
peptid
heart
rate
blood
pressur
observ
dose
data
shown
peptid
previous
report
substrat
purifi
human
enzym
vicker
et
al
studi
confirm
wang
et
al
also
catalyz
convers
predomin
cardiovascular
form
apelin
vitro
result
unexpect
sinc
pmpf
sequenc
figur
conform
consensu
sequenc
hydrolysi
prox
prohydrophob
vicker
et
al
support
assay
product
de
novo
metabol
demonstr
compar
potenc
synthet
tabl
result
consist
studi
report
small
proport
cleav
rat
vivo
murza
et
al
previous
demonstr
endotheli
express
apelin
kleinz
davenport
kleinz
et
al
use
antibodi
specif
apelin
isoform
contain
ctermin
phenylalanin
figur
consist
report
other
use
altern
strategi
detect
apelin
express
sheikh
et
al
also
express
endothelium
donoghu
et
al
ham
et
al
rais
possibl
endotheli
process
produc
studi
gener
antibodi
crossreact
apelin
isoform
without
ctermin
phenylalanin
allow
select
identif
human
heart
lung
li
specif
local
endothelium
apelin
receptor
also
express
suggest
possibl
autocrin
signal
metabolit
tissu
importantli
human
pah
lung
endotheli
apelin
express
known
reduc
alastalo
et
al
kim
et
al
stain
detect
hydrolysi
assum
inactiv
apelin
peptid
wang
colleagu
recent
report
product
exhibit
reduc
absent
cardiovascular
action
compar
parent
molecul
wang
et
al
howev
emerg
evid
structur
activ
studi
suggest
ctermin
phenylalanin
critic
residu
apelin
biolog
activ
fan
et
al
medhurst
et
al
hypothesi
compar
may
retain
signific
activ
inde
result
show
nanomolar
affin
nativ
human
apelin
receptor
exhibit
reduct
bind
affin
compar
parent
peptid
consist
previou
studi
ctermin
phenylalanin
replac
alanin
fan
et
al
medhurst
et
al
remov
el
messari
et
al
iturrioz
et
al
minim
loss
receptor
affin
similarli
substitut
ctermin
phenylalanin
dphenylalanin
result
decreas
receptor
bind
affin
modest
compar
substitut
residu
known
import
bind
murza
et
al
overal
studi
show
loss
ctermin
phenylalanin
apelin
isoform
significantli
alter
receptor
bind
apelin
receptor
habata
et
al
therefor
next
show
inhibit
forskolinstimul
camp
potenc
less
agreement
previou
report
alanin
dphenylalanin
substitut
medhurst
et
al
murza
et
al
el
messari
et
al
iturrioz
et
al
ceraudo
et
al
therefor
studi
confirm
signal
preserv
respons
receptor
bind
addit
g
proteindepend
signal
activ
apelin
receptor
caus
recruit
receptor
intern
evan
et
al
assay
behav
full
agonist
human
apelin
receptor
reduct
potenc
compar
abil
induc
receptor
intern
without
ctermin
phenylalanin
report
fan
et
al
howev
shown
second
group
exhibit
markedli
reduc
potenc
efficaci
recruit
intern
rat
apelin
receptor
el
messari
et
al
iturrioz
et
al
ceraudo
et
al
importantli
compar
bias
agonist
g
proteindepend
independ
signal
apelin
modul
vascular
tone
cardiac
contractil
vitro
vivo
japp
et
al
maguir
et
al
barn
et
al
brame
et
al
therefor
expect
found
contract
human
saphen
vein
equal
potenc
efficaci
compar
previou
data
maguir
et
al
brame
et
al
potent
inotrop
mous
pace
right
ventricl
human
pace
atria
next
investig
vivo
action
anesthet
rat
compar
previous
publish
data
brame
et
al
metabolit
caus
smaller
signific
drop
blood
pressur
contrast
wang
colleagu
wang
et
al
report
show
sustain
effect
blood
pressur
min
administr
mice
vivo
although
peptid
appear
show
initi
compar
reduct
blood
pressur
first
min
experi
interestingli
author
also
show
rapidli
cleav
vitro
vivo
suggest
cleavag
product
may
contribut
observ
sustain
respons
might
expect
halflif
cleavag
product
like
short
therefor
respons
infus
observ
initi
min
experi
agreement
hypothesi
rat
studi
brame
et
al
halflif
less
min
human
less
min
japp
et
al
importantli
firstinman
studi
infus
result
increas
forearm
blood
flow
magnitud
previous
obtain
brame
et
al
confirm
metabolit
vasodil
human
vivo
acid
proapelin
deriv
prepropeptid
contain
number
pair
basic
amino
acid
residu
possibl
cleavag
site
endopeptidas
produc
isoform
tatemoto
et
al
habata
et
al
ident
peptidas
remain
unknown
studi
report
direct
cleavag
proapelin
proprotein
convertas
subtilisinkexin
furin
bypass
gener
longer
isoform
shin
et
al
posttransl
modif
result
predomin
apelin
isoform
detect
human
cardiovascular
tissu
plasma
de
mota
et
al
kleinz
davenport
maguir
et
al
zhen
et
al
put
metabolit
cardiac
peptid
focu
studi
also
explor
pharmacolog
sever
import
apelin
isoform
better
understand
apelin
structur
activ
relationship
name
minimum
activ
fragment
describ
amino
acid
substitut
studi
propos
consensu
amino
acid
within
import
receptor
bind
activ
narayanan
et
al
ctermin
phenylalanin
adjac
prolin
ntermin
pyroglutam
acid
identifi
import
investig
whether
truncat
peptid
retain
signific
bind
function
activ
hypothesi
like
repres
minimum
activ
fragment
shortest
fragment
contain
identifi
import
amino
acid
result
competit
bind
experi
recruit
assay
support
hypothesi
data
previou
public
show
diminish
signal
calcium
mobil
methionin
posit
remov
medhurst
et
al
zhang
et
al
other
demonstr
activ
without
ntermin
pyroglutam
acid
vivo
pisarenko
et
al
residu
arginin
methionin
indispens
requir
form
crucial
rprl
motif
provid
steric
volum
langelaan
et
al
macaluso
glen
gerbier
et
al
contrast
although
ctermin
phenylalanin
shown
make
specif
contact
within
bind
pocket
apelin
receptor
iturrioz
et
al
experiment
data
suggest
remov
abolish
bind
function
activ
earli
alanin
scan
studi
indic
replac
ctermin
phenylalanin
alanin
abolish
signal
calcium
mobil
medhurst
et
al
receptor
intern
fan
et
al
howev
conflict
data
report
suggest
antagonist
apelin
receptor
term
signal
de
mota
et
al
hypotens
effect
lee
et
al
studi
found
resembl
receptor
bind
cell
base
assay
vasoconstrictor
bioassay
base
result
behav
apelin
agonist
evid
receptor
antagon
despit
unclear
biosynthet
pathway
report
equal
higher
bind
affin
potenc
inhibit
camp
accumul
induc
receptor
intern
compar
medhurst
et
al
el
messari
et
al
investig
assay
consist
found
higher
bind
affin
higher
potenc
camp
assay
intriguingli
appear
bias
compar
g
protein
signal
rel
refer
agonist
suggest
ntermin
extens
may
result
peptid
stabil
differ
conform
apelin
receptor
may
mechan
apelin
receptor
activ
finetun
cellular
level
past
studi
suggest
possibl
link
apelin
receptor
renin
angiotensin
system
exampl
apelin
knockout
mice
show
age
stressassoci
cardiac
contractil
defect
similar
cardiac
phenotyp
knockout
mice
kuba
et
al
apelin
receptor
knockout
mice
sensit
pressor
effect
angiotensin
ii
ishida
et
al
interestingli
express
reduc
apelin
knockout
mice
apelin
upregul
express
indic
apelin
may
reciproc
impact
sato
et
al
receptor
level
apelin
receptor
shown
physic
interact
angiotensin
receptor
type
chun
et
al
forc
low
affin
state
reduc
bind
signal
angiotensin
ii
siddique
et
al
reduc
apelin
express
due
heart
failur
angiotensin
ii
administr
restor
blockad
iwanaga
et
al
oppos
effect
angiotensin
ii
shown
health
diseas
heart
failur
atherosclerosi
obesitydiabet
ashley
et
al
gurzu
et
al
iwanaga
et
al
zhong
et
al
chun
et
al
barn
et
al
siddique
et
al
figur
studi
contribut
evid
upregul
diseas
act
may
result
gener
activ
metabolit
therefor
compensatori
mainten
apelin
receptor
signal
howev
limit
studi
measur
level
apelin
peptid
plasma
patient
receiv
therapi
would
hypothes
level
would
elev
decreas
compar
control
conclus
studi
confirm
cleav
demonstr
biolog
activ
human
apelin
receptor
vitro
cardiovascular
system
rat
human
vivo
result
also
clarifi
shortest
activ
apelin
fragment
agonist
potent
agonist
therefor
studi
show
report
enhanc
activ
cardiovascular
diseas
significantli
compromis
benefici
effect
apelin
base
therapi
exampl
pah
author
contribut
either
concept
design
work
py
ab
ad
ms
rg
jc
iw
apd
jm
acquir
analyz
data
interpret
data
py
rk
ab
ad
ms
apd
jm
author
agre
account
aspect
work
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
